An overview of clinical trial experience with epanolol.
This overview of the safety and efficacy of the antianginal agent epanolol presents key features of the data from an international trial programme involving 1274 subjects. Additional information on the most frequently occurring possible adverse reactions is drawn from 2506 patients, which includes those in ongoing studies. Pooled analyses show that epanolol is as effective as reference therapies (nifedipine and atenolol), as assessed by work output during exercise tests, and in studies of anginal attack rate or work output during 12 months of treatment there was no evidence of tachyphylaxis with epanolol. Epanolol has a favourable safety profile, which compares well with those for placebo and for active antianginal therapies.
Blake
P
P
ICI Pharmaceuticals Group, Wilmington, Delaware.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology; D044482:Benzeneacetamides; D002986:Clinical Trials as Topic; D006801:Humans; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D044482:Benzeneacetamides; D011412:Propanolamines; C038616:epanolol